Lurbinectedin is a chemotherapeutic agent that has been explored in combination with immunotherapies to enhance its anti-tumor effects.

According to a study published in the Journal of Clinical Oncology 1, lurbinectedin has been combined with pembrolizumab, a PD-1 checkpoint inhibitor. In preclinical studies, this combination demonstrated synergistic anti-tumor activity in various cancer models, indicating potential for clinical use.

Additionally, lurbinectedin has been investigated in combination with atezolizumab, another PD-L1 checkpoint inhibitor 2, and talabotulinumab, a TRAIL receptor agonist 3. These studies aim to determine whether adding immunotherapy to lurbinectedin can enhance treatment efficacy and overcome resistance to single-agent therapy.



Sources:

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324418/

[2] https://pubmed.ncbi.nlm.nih.gov/32744134/

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131425/